AR079429A1 - CAPSULES OF PHARMACEUTICAL AND ESTERS ACTIVE PRINCIPLES OF POLYINSATURATED FATTY ACIDS - Google Patents

CAPSULES OF PHARMACEUTICAL AND ESTERS ACTIVE PRINCIPLES OF POLYINSATURATED FATTY ACIDS

Info

Publication number
AR079429A1
AR079429A1 ARP100104271A ARP100104271A AR079429A1 AR 079429 A1 AR079429 A1 AR 079429A1 AR P100104271 A ARP100104271 A AR P100104271A AR P100104271 A ARP100104271 A AR P100104271A AR 079429 A1 AR079429 A1 AR 079429A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical
capsule according
pharmaceutical capsule
fatty acids
microcapsules
Prior art date
Application number
ARP100104271A
Other languages
Spanish (es)
Inventor
Duena Antonio Parente
Paolo Carminati
Original Assignee
Defiante Farmaceutica Sa
Gp Pharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defiante Farmaceutica Sa, Gp Pharm Sa filed Critical Defiante Farmaceutica Sa
Publication of AR079429A1 publication Critical patent/AR079429A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composicion farmacéutica en forma de cápsula que contiene ésteres alquílicos de ácidos grasos poliinsaturados (PUFA) y principios activos farmacéuticos para el tratamiento y/o prevencion de enfermedades cardiovasculares y/o procesos inflamatorios. Reivindicacion 1: Cápsula farmacéutica que comprende una suspension de microcápsulas poliméricas que comprenden al menos un polímero y al menos un principio activo farmacéutico seleccionado del grupo formado por antagonistas de los canales de calcio, betabloqueantes, antiagregantes plaquetarios, anticoagulantes y antiinflamatorios no esteroideos, estando dichas microcápsulas suspendidas en un aceite que contiene ésteres alquílicos de ácidos grasos poliinsaturados. Reivindicacion 2: Cápsula farmacéutica segun la reivindicacion 1, donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos pertenecen a la serie omega-3. Reivindicacion 3: Cápsula farmacéutica segun la reivindicacion 2, donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos se seleccionan del grupo formado por ácido eicosapentaenoico, ácido docosahexaenoico, y/o sus mezclas. Reivindicacion 12: Cápsula farmacéutica segun la reivindicacion 1, donde el polímero de dichas microcápsulas se selecciona del grupo formado por proteínas, poliésteres, poliacrilatos, policianoacrilatos, polisacáridos, polietilenglicol y/o sus mezclas. Reivindicacion 14: Cápsula farmacéutica segun la reivindicacion 1, donde dichas microcápsulas representan entre el 0,001% y el 80% del peso total de la cápsula. Reivindicacion 17: Cápsula farmacéutica segun la reivindicacion 1, donde la composicion de la cubierta de dicha cápsula se selecciona del grupo formado por gelatina, hidroxipropilmetilcelulosa, pululano, almidones modificados, carragenanos y/o sus mezclas. Reivindicacion 19: Cápsula farmacéutica segun la reivindicacion 1, donde dicha cápsula tiene un recubrimiento entérico. Reivindicacion 20: Cápsula farmacéutica segun la reivindicacion 1, para el tratamiento y/o prevencion de enfermedades cardiovasculares. Reivindicacion 21: Cápsula farmacéutica segun la reivindicacion 1, para el tratamiento de enfermedades y/o procesos que cursan con inflamacion y/o dolor.Pharmaceutical capsule composition containing alkyl esters of polyunsaturated fatty acids (PUFA) and pharmaceutical active ingredients for the treatment and / or prevention of cardiovascular diseases and / or inflammatory processes. Claim 1: Pharmaceutical capsule comprising a suspension of polymer microcapsules comprising at least one polymer and at least one pharmaceutical active ingredient selected from the group consisting of calcium channel blockers, beta blockers, platelet antiaggregants, anticoagulants and non-steroidal anti-inflammatory drugs, said said being. microcapsules suspended in an oil containing alkyl esters of polyunsaturated fatty acids. Claim 2: Pharmaceutical capsule according to claim 1, wherein the polyunsaturated fatty acids of said alkyl esters belong to the omega-3 series. Claim 3: Pharmaceutical capsule according to claim 2, wherein the polyunsaturated fatty acids of said alkyl esters are selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, and / or mixtures thereof. Claim 12: Pharmaceutical capsule according to claim 1, wherein the polymer of said microcapsules is selected from the group consisting of proteins, polyesters, polyacrylates, polycyanoacrylates, polysaccharides, polyethylene glycol and / or mixtures thereof. Claim 14: Pharmaceutical capsule according to claim 1, wherein said microcapsules represent between 0.001% and 80% of the total weight of the capsule. Claim 17: Pharmaceutical capsule according to claim 1, wherein the composition of the cover of said capsule is selected from the group consisting of gelatin, hydroxypropyl methylcellulose, pululane, modified starches, carrageenans and / or mixtures thereof. Claim 19: Pharmaceutical capsule according to claim 1, wherein said capsule has an enteric coating. Claim 20: Pharmaceutical capsule according to claim 1, for the treatment and / or prevention of cardiovascular diseases. Claim 21: Pharmaceutical capsule according to claim 1, for the treatment of diseases and / or processes that occur with inflammation and / or pain.

ARP100104271A 2009-11-20 2010-11-18 CAPSULES OF PHARMACEUTICAL AND ESTERS ACTIVE PRINCIPLES OF POLYINSATURATED FATTY ACIDS AR079429A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200931026A ES2363964B1 (en) 2009-11-20 2009-11-20 CAPSULES OF PHARMACEUTICAL ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.

Publications (1)

Publication Number Publication Date
AR079429A1 true AR079429A1 (en) 2012-01-25

Family

ID=43498493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104271A AR079429A1 (en) 2009-11-20 2010-11-18 CAPSULES OF PHARMACEUTICAL AND ESTERS ACTIVE PRINCIPLES OF POLYINSATURATED FATTY ACIDS

Country Status (4)

Country Link
AR (1) AR079429A1 (en)
ES (1) ES2363964B1 (en)
TW (1) TW201141470A (en)
WO (1) WO2011060944A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385240B1 (en) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
ITMI20112221A1 (en) 2011-12-05 2013-06-06 Altergon Sa STABLE FORMULATIONS IN JELLY CAPSULES SPRINGS OF PIASTRINICAL ANTI-AGGREGATES, OMEGA-3 FATTY ACIDS AND AMYLOSUS
EP2836206A4 (en) * 2012-04-10 2015-11-04 Rubicon Res Private Ltd Controlled release pharmaceutical formulations of direct thrombin inhibitors
WO2014007779A1 (en) * 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
WO2014007780A1 (en) * 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
CN103626689B (en) * 2012-08-24 2016-03-09 上海医药工业研究院 A kind of preparation method of intermediate of Eliquis
US20150366813A1 (en) * 2014-06-20 2015-12-24 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
CN106620707B (en) * 2017-03-14 2019-06-07 牡丹江医学院 A kind of pharmaceutical composition and its preparation method and application preventing and treating myocardial ischemia
CN114869857B (en) * 2022-05-12 2023-04-04 郑州大学第一附属医院 Argatroban particles, preparation and preparation method thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (en) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS5920230A (en) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト Drug containing piruprophen
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4954346A (en) 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US4857552A (en) 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
FR2660555B1 (en) 1990-04-06 1994-09-16 Rhone Poulenc Sante KETOPROFEN OIL CAPSULE.
DE69109282T2 (en) 1990-04-11 1995-09-28 Upjohn Co METHOD FOR FLAVORING IBUPROFEN.
CA2039742A1 (en) 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
CH683149A5 (en) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
KR100338851B1 (en) 1994-03-15 2002-10-12 센주 세이야꾸 가부시키가이샤 How to stabilize pranopropene and stable pranopropene
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
AU6390096A (en) 1995-07-20 1997-02-18 Pharmacia & Upjohn Company Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
WO1997033568A1 (en) 1996-03-12 1997-09-18 Novartis Ag Filled gelatin capsules having a reduced degree of cross-linking
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
WO2001021154A2 (en) 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE10026699A1 (en) 2000-05-30 2001-12-06 Basf Ag Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base
EA005494B1 (en) 2000-08-25 2005-02-24 Кова Компани, Лтд. Ibuprofen solutions for capsule- filling and capsule preparations
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6673944B2 (en) 2001-02-28 2004-01-06 Taro Pharmaceutical Industries, Ltd. Preparation of warfarin sodium from warfarin acid
ITMI20020731A1 (en) * 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa PHARMACEUTICAL COMPOSITIONS FOR ACETYLSALICYLIC ACID AND OMEGA-3 OILS
ITFI20020144A1 (en) 2002-08-01 2004-02-02 Menarini Farma Ind STABILIZED TOPICAL FORMULATIONS CONTAINING KETOPROFENE.
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
GB0325603D0 (en) 2003-11-03 2003-12-10 Sandoz Ag Organic compounds
JP2007512372A (en) 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Carvedilol salts, corresponding compositions, delivery and / or treatment methods
US20080311207A1 (en) 2004-09-08 2008-12-18 Manoj Varshney Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis
DE602005018387D1 (en) 2004-10-06 2010-01-28 Eisai R&D Man Co Ltd MEDICAL COMPOSITION, PROCESS FOR YOUR HDI-HYDROPYRIDINE COMPOUND IN A MEDICAL COMPOSITION
ES2255426B1 (en) * 2004-10-19 2007-08-16 Gp Pharm, S.A. PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA).
WO2006081518A2 (en) 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
EP1688129B1 (en) 2005-02-02 2015-07-08 Omega Pharma Nordic AB New therapeutic formulation
CA2646131C (en) * 2005-03-21 2018-09-04 Vicus Therapeutics Spe 1, Llc Compositions and methods for ameliorating cachexia
EA200800451A1 (en) * 2005-07-28 2008-08-29 Релайэнт Фармасьютикалз, Инк. TREATMENT OF DIHYDROPYRIDINE BLOCKERS OF CALCIUM CHANNELS AND FATTY ACIDS OF OMEGA-3 AND THEIR COMBINED PRODUCT
WO2007103557A2 (en) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
KR100913791B1 (en) 2006-07-21 2009-08-26 한미약품 주식회사 S---amlodipine camsylate or hydrate thereof and pharmaceutical composition containing same
WO2008062435A2 (en) 2006-08-15 2008-05-29 Alkem Laboratories Ltd. Stabilised dosage forms of amlodipine besylate
EP1894561A1 (en) 2006-08-30 2008-03-05 Dr. Reddy's Laboratories Ltd. Dipyridamole pharmaceutical compositions
ATE498626T1 (en) 2006-09-25 2011-03-15 Adamed Sp Zoo NEW CLOPIDOGREL SALT AND ITS CRYSTALLINE FORMS
BRPI0719183A2 (en) 2006-10-13 2014-06-03 Reliant Pharmaceuticals Inc TREATMENT WITH ANTIARRHYTHICS AND FATTY ACIDS OF OMEGA-3 AND A COMBINATION PRODUCT OF THESE
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
WO2008070950A1 (en) 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
KR20080055356A (en) 2006-12-15 2008-06-19 에스케이케미칼주식회사 Inclusion complex of clopidogrel and beta-cyclodextrin
WO2008088808A1 (en) 2007-01-16 2008-07-24 Reliant Pharmaceuticals, Inc. Treatment with non-steroidal anti-inflammatory drugs and omega-3 fatty acids, and a combination product thereof
CA2683611A1 (en) 2007-04-09 2008-10-16 Usv Limited Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions

Also Published As

Publication number Publication date
WO2011060944A8 (en) 2011-10-27
ES2363964B1 (en) 2012-08-22
ES2363964A1 (en) 2011-08-22
TW201141470A (en) 2011-12-01
WO2011060944A2 (en) 2011-05-26
WO2011060944A3 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
AR079429A1 (en) CAPSULES OF PHARMACEUTICAL AND ESTERS ACTIVE PRINCIPLES OF POLYINSATURATED FATTY ACIDS
PE20142459A1 (en) DPA-ENRICHED COMPOSITIONS OF POLYINSATURATED OMEGA 3 FATTY ACIDS IN FREE ACID FORM
AR095182A1 (en) COMPOSITIONS OF STATINS AND FATTY ACIDS OMEGA-3
ES2279864T3 (en) POTENTIAL OF THERAPEUTIC EFFECTS OF POLYINSATURATED FATTY ACIDS.
MX2012005744A (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases.
JP2015143248A5 (en)
CU20140151A7 (en) PHARMACEUTICAL COMPOSITION USEFUL IN THE PREVENTION OF A GREATER CARDIOVASCULAR EVENT
JP2015520235A5 (en)
JP2015527386A5 (en)
RU2014141406A (en) Omega-3 Fatty Acid Ester Compositions
NI201100013A (en) SALICYLATES ACETYLATED WITH FATTY ACIDS AND THEIR USES.
AR082930A1 (en) COMPOSITIONS THAT INCLUDE AN OILY MIXTURE OF FATTY ACIDS, A TENSIOACTIVE AND A STATIN
MX342216B (en) Fatty acid compositions.
WO2006078457A3 (en) Use of resolvins to treat gastrointestinal diseases
JP2014231513A5 (en)
PE20091076A1 (en) COMPOSITION INCLUDING POLYINSATURATED FATTY ACIDS AND ACTIVATED VEGETABLE CARBON
UY31741A (en) CAPSULE FOR THE PREVENTION OF CARDIOVASCULAR DISEASES
AR110343A1 (en) NUTRITIONAL COMPOSITIONS CONTAINING BUTIRATE AND USES OF THE SAME
CL2019000607A1 (en) Composition for topical application with antifungal activity.
HRP20230267T1 (en) Compositions for the treatment of hypertension
BR112015013988A2 (en) abrasive coatings for peroxide containing compositions
JP2017514874A5 (en)
BR112018001164A2 (en) compound of the general formula, pharmaceutical composition and method for the treatment of cardiovascular disease
BR112021010335A2 (en) Preparation comprising a probiotic strain and a polyunsaturated fatty acid component
AR101724A1 (en) PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION INCLUDING AN INHIBITOR OF THE TRANSFER PROTEIN OF THE CHOLESTERILE ESTER AND INHIBITORS OF THE HMG COA REDUCTASA

Legal Events

Date Code Title Description
FB Suspension of granting procedure